Key result
Adding NEPi and ECEi to ACEi fails to further reduce blood pressure in hypertensive rats.
Why the study?
The role of triple vasopeptidase inhibition combining ACEi, NEPi, and ECEi in controlling blood pressure in spontaneously hypertensive rats was unclear.
Does triple vasopeptidase inhibition (ACEi + NEPi + ECEi) reduce mean arterial blood pressure more than ACEi alone in spontaneously hypertensive rats?
Does triple vasopeptidase inhibition (ACEi + NEPi + ECEi) reduce mean arterial blood pressure more than ACEi alone in spontaneously hypertensive rats?
In spontaneously hypertensive rats, the addition of NEPi and ECEi to ACEi did not provide further blood pressure lowering benefits beyond ACEi alone at the tested doses.
No takes yet. Share an insight, caveat, or question.
No additive BP lowering with NEPi/ECEi plus ACEi in SHR; leaves open utility in other models or species.
Daull et al. (2004) studied hypertension. Triple vasopeptidase inhibition (ACEi, NEPi, ECEi) vs. ACEi alone was evaluated on mean arterial blood pressure. In spontaneously hypertensive rats, adding a neutral endopeptidase inhibitor and an endothelin-converting enzyme inhibitor to an ACE inhibitor did not provide further blood pressure reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: